Update shared on01 Aug 2025
Fair value Decreased 18%BioXcel Therapeutics’ consensus price target was revised downward due to significantly reduced revenue growth forecasts, partly offset by improved profit margins, resulting in a new fair value estimate of $19.00.
What's in the News
- The pivotal Phase 3 SERENITY At-Home clinical trial of BXCL501 for the acute treatment of agitation in bipolar disorders or schizophrenia at home has completed patient visits, with topline data expected soon to support a supplemental New Drug Application for outpatient label expansion.
- An independent Data Safety Monitoring Board has twice recommended the SERENITY At-Home trial continue without modification after reviews of unblinded safety data, underscoring a favorable safety profile to date.
- BioXcel Therapeutics has submitted a pre-sNDA meeting package to the FDA and plans an August meeting to confirm alignment on the content for the planned submission to expand IGALMI’s label for at-home use.
- BXCL501 (IGALMI) is an orally dissolving film of dexmedetomidine granted Breakthrough Therapy designation by the FDA for agitation in schizophrenia, bipolar disorder, and dementia; it addresses a large unmet need as there are currently no FDA-approved therapies for at-home agitation treatment in these populations.
Valuation Changes
Summary of Valuation Changes for BioXcel Therapeutics
- The Consensus Analyst Price Target has significantly fallen from $23.25 to $19.00.
- The Consensus Revenue Growth forecasts for BioXcel Therapeutics has significantly fallen from 224.4% per annum to 178.5% per annum.
- The Net Profit Margin for BioXcel Therapeutics has significantly risen from 10.54% to 12.20%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.